Adenine arabinoside and human interferon are currently being evaluated in clinical trials against herpes-and poxvirus infections. Interferon production is aiso a normal antiviral response. It is therefore important to examine the combined actions of interferon and antiviral arabinosides for possible synergy or antagonism. We have examined the antiviral activities of human fibroblast interferon, adenine arabinoside, hypoxanthine arabinoside, and adenine arabinoside 5'-monophosphate individually, using plaque inhibition of vaccinia and herpes simplex type 2 viruses in human skin fibroblast cultures. By combining doses of interferon and arabinosides that, acting alone, give intermediate degrees of plaque inhibition, we were able to compare the combined antiviral activity with that calculated from the activity of each inhibitor alone, assuming that the activities are statistically independent. Our results show that the plaque-inhibitory activities ofinterferon and the arabinosides tested are statistically independent. The results also show that the arabinosides do not destabilize the antiviral state previously induced by interferon, and that interferon pretreatment does not interfere with subsequent arabinoside action in infected cells. We have also found that arabinosides do not affect the induction of interferon synthesis by either Newcastle disease virus or double-stranded ribonucleic acid, and are not themselves interferon inducers.
syladenine, Ara-A) and human interferon are currently being evaluated in clinical trials for therapeutic use against several deoxyribonucleic acid virus infections, including herpes simplex types 1 and 2 (HSV-1 and -2), varicellazoster, cytomegalovirus, and vaccinia (2 to 9, 14) . Hypoxanthine arabinoside (Ara-Hx) is produced in vivo and in vitro by deamination of Ara-A, catalyzed by the enzyme adenosine deaminase; it has significantly lower antiviral activity than the parent compound (4, 5, 11) . Ara-AMP, the 5'-monophosphate ofAra-A, also has inhibitory activity against the large deoxyribonucleic acid viruses and is presently in phase I clinical trials. For brevity, we refer to all three of these compounds as "arabinosides."
The interferon system is an important component of the vertebrate host's natural antiviral defenses (3) . Therefore, it seemed desirable to examine the effects of any potential chemotherapeutic agent on both the production I Present address: Department of Pediatrics, School of Medicine, University of California at Los Angeles, Los Angeles, CA 90024. and the antiviral activity of interferon. We have done so using human diploid foreskin fibroblasts (HSF) infected with either HSV-2 or vaccinia virus. COur results show that the arabinosides tested (Ara-A, Ara-Hx, and Ara-AMP) neither antagonize nor enhance the antiviral activity of HSF interferon; that is, the antiviral activities of the arabinosides and interferon are statistically independent. Our approximately 300 PFU/cell in 0.2 ml of NDV-containing allantoic fluids for 90 min at room temperature. After adsorption, the cultures were washed twice with 2 ml of Tris buffer and refed 2 ml of maintenance medium. For poly(I:C), confluent 35-mm cultures were washed once with 2 ml of MEM and refed 1 ml of MEM, 1% FBS, 100 ,ug of diethylaminoethyldextran (Pharmacia) per ml, and 10 ,ug ofpoly(I:C) (P-L Biochemicals) per ml. After incubation for 3 h at 370C, the cultures were washed three times with 2 ml of MEM and refed 2 ml of maintenance medium. Twenty-four hours after the beginning of induction, culture fluids were removed, pooled for duplicates, and dialyzed at pH 2.2 and pH 7.4 as described (18) . The media were then clarified by centrifugation and stored at -20°C. Interferon yields were measured by a modification of the micro dye-uptake method previously described (1): confluent HSF monolayers in Falcon microtest II plates were incubated overnight in 0.1 ml of maintenance medium per well containing serial threefold dilutions of interferons. The cultures were then washed with Tris buffer, infected with 10 PFU of largeplaque EMC virus per cell and refed 0.12 ml of maintenance medium per well. After 24 h at 37°C, the cultures were fixed in methanol and stained with 1% aqueous crystal violet. Interferon titers given in Table 1 are the reciprocal of the dilution giving approximately 50% protection of the microtest cultures from destruction by EMC virus. Arabinosyl compounds. Ara-A, Ara-Hx, Ara-AMP, and adenosine deaminase inhibitor (ADAI) (24) were obtained from Parke-Davis and were the kind gifts of James D. Connor. The Ara-Hx was further purified by high-pressure liquid chromatog-raphy as previously described (5). Stock solutions were stored at -20°C. ADAI was used at a concentration of 0.83 ,ug/ml in all experiments with Ara-A and Ara-AMP to prevent deamination, as previously described (5) . This concentration of ADAI has no intrinsic antiviral activity in the systems used here. ADAI was not used in experiments with Ara-Hx.
RESULTS
Antiviral activity f arabinosides against vaccinia virus and HSV-2. Initially the antiviral activities of Ara-A, Ara-Hx, and Ara-AMP were measured individually, using plaque inhibition against vaccinia virus or HSV-2. These experiments were similar to those reported previously (5, 10) Combined antiviral activities of arabinosides and interferon. The strategy of these experiments was as follows: confluent HSF monolayers were incubated overnight in maintenance medium containing serial threefold dilutions of human fibroblast interferon. The cultures were then washed, infected with 60 PFU of either vaccinia virus or HSV-2 per culture, and replenished with maintenance medium containing doses of arabinosides chosen from the data in Fig. 1 and 2 to give approximately 25% plaque inhibition. "Drug controls" refers to cultures pretreated with interferon-free medium and maintained postinfection in medium containing the individual arabinosides. "Interferon controls" refers to cultures pretreated with interferon dilutions but maintained postinfection in drug-free medium. "Virus controls" refers to cultures pretreated with interferonfree medium and maintained pdstinfection in drug-free medium. At 48 h postinfection, the plaques were scored and expressed as percentage of virus controls. Results representative of the experiments with vaccinia virus are shown in i.e., cultures pretreated with interferon dilutions and post-treated in drug-free medium. The results are equivalent to a plaque-inhibition assay of our interferon preparation, using vaccinia virus for challenge. In panels B, C, and D the drug controls are shown by the horizontal dotted line. Thus the dose of Ara-AMP used (0.04 ,g/ml) produced approximately 15% inhibition of plaque development, Ara-A (0.025 ,ug/ml) produced approximately 21% plaque inhibition, and Ara-Hx (1.0 ,ug/ml) produced approximately 30% plaque inhibition. In panels B through D, circles indicate the observed results for cultures pretreated with interferon dilutions (shown on the abscissa) and post-treated with these doses of arabinosides.
Our criterion for antagonism or synergy between the antiviral actions of arabinosides and interferon is as follows: if P1 is the fraction of control plaques observed in the presence of a given amount of interferon and P2 is the fraction of control plaques observed in the presence ANTIMICROB. AGENTS CHEMOTHER.
of a given amount of arabinoside, then the fraction of control plaque number observed in the presence of both substances is the product (P1)(P2) if the inhibitory activities are statistically independent. We use antagonism to denote plaque survival in excess ofthat calculated assuming statistical independence, and we use synergy to denote plaque survival less than that calculated assuming statistical independence. Thus the expected results (shown in Fig.  3 by squares) are calculated by multiplying the fraction of control plaque number observed at a given dose of interferon and the fraction of control plaque number observed at the dose of arabinoside used. In Fig. 3 it is evident that the expected and observed results coincide quite closely. Hence we conclude that the antiviral activities of interferon and each of the arabinosides tested are statistically independent.
Identical experiments were performed using HSV-2. Comparison of the abscissae in Fig. 3A and 4A shows that the median inhibitory dose of interferon was approximately eightfold higher for HSV-2 than for vaccinia virus. In  Fig. 4 , the inhibition due to arabinosides alone (drug controls) is again indicated by horizontal dotted lines. In this case, the dose of Ara-A (0.1 ,ug/ml) produced approximately 11% plaque inhibition, Ara-AMP (0.2 ,tg/ml) produced approximately 23% plaque inhibition, and Ara-Hx (6.0 jig/ml) produced approximately 23% plaque inhibition. In each case, the experiments with combined inhibitors (Fig. 4B to D) gave observed results that were experimentally indistinguishable from the expected results calculated assuming statistical independence of the inhibitory activities. For both vaccinia virus and HSV-2, results identical to those obtained for the interferon controls (panel A) were given by cells treated only with ADAI postinfection. We conclude, insofar as HSV-2 and vaccinia virus are concerned, that the plaque-inhibitory activities of human fibroblast interferon and these arabinosides are statistically independent and show no evidence of antagonism or synergy in their actions.
Two further conclusions can be drawn from the results given in Fig. 3 nism between the inhibitory actions of interferon and arabinosides. Conversely, prior exposure of cells to interferon does not interfere with the antiviral action of subsequent doses of arabinosides.
Effect of arabinosides on establishment of the antiviral state induced by interferon. The preceding experiments (Fig. 3 and 4) 10 ,ug of Ara-Hx per ml). Controls contained interferon dilutions without arabinosides, with and without ADAI. The cultures were then washed, infected with 60 PFU of small-plaque EMC virus per culture, and scored at 36 h postinfection. Since the arabinosides were washed out of the cultures before infection, and since EMC is ribonucleic acid virus insensitive to the inhibitory activities of these arabinosides (not inhibited in cells even when treated concurrently with arabinosides; our unpublished data), any inhibition of EMC plaque formation in this experiment must be attributed to the antiviral state established in the cells before infection, in response to interferon. The results are shown in Fig. 5 . The inhibition curves were identical whether the cells were pretreated with interferon alone or in the presence of Ara-A, Ara-AMP, or Ara-Hx. The results were unchanged for cells treated with interferon and ADAI (data not shown). Hence, neither ADAI nor high concentrations of arabinosides inhibited the establishment of the antiviral state induced by interferon.
Effect of arabinosides on induction of interferon synthesis. A final set of experiments was designed to test whether ADAI or arabinosides interfere with the induction of interferon synthesis by virus or poly(I:C), or might themselves be interferon inducers. Confluent HSF monolayers were induced by NDV or poly(I:C) as described in Materials and Methods and refed maintenance medium containing Ara-A (5 ,tg/ml) or Ara-AMP (8 ,g/ml), each with and without ADAI (0.83 ,ug/ml). Ara-Hx was not tested in these experiments, but was produced by deamination of Ara-A in cultures not containing ADAI. Controls contained no additions. At 24 h postinduction, the extracellular media were removed and the interferon activity was quantitated as described in Materials and Methods (Table 1) . Neither arabinosides nor ADAI alone or in combination caused synthesis of any detectable interferon. Control NDV-induced cultures produced 1,200 U of interferon, and neither arabinosides nor ADAI markedly affected this yield. Control poly(I:C)-induced cultures produced about 4,000 U of interferon, and this also was not significantly affected by arabinosides or ADAI. Thus arabinosides and/ or ADAI do not impair the production of interferon by human fibroblasts in response to virus or poly(I:C).
DISCUSSION
The experiments reported herein were designed to test whether the antiviral arabinosides Ara-A, Ara-Hx, and Ara-AMP demonstrate antagonistic or synergistic effects upon the production and antiviral activity of human interferon. Interferon production and action are important components of the early antiviral response in vivo (3), and there is increasing evidence that interferon production also serves a regulatory purpose in both cell-mediated and humoral immunity (12, (15) (16) (17) (20) (21) (22) . Therefore it seems desirable to examine the effects of any potential antiviral chemotherapeutic agent on both aspects of the interferon response. Our experiments provide a model by which the combined activities of interferon and antiviral drugs can be examined in vitro. Such information may prove to be important in the chemotherapy of viral diseases since a rational approach to antiviral chemotherapy would require that drugs do not impair the endogenous interferon response. In addition, combined therapy with antiviral drugs and exogenous interferon may provide increased clinical efficacy, provided that the activities are not antagonistic.
We chose HSV-2 and vaccinia viruses as representatives of the herpes-and poxvirus groups. It would also be of interest to examine other herpesviruses such as varicella-zoster and cytomegalovirus. Our experiments measured the antiviral activities of interferon and arabinosides alone and in combination; by combining doses of each that, acting alone, would give intermediate degrees of plaque inhibition, we were able to compare the combined antiviral effects with those calculated from the activity of each inhibitor alone, assuming that the activities are statistically independent. Our results are indistinguishable from those calculated on this basis and lead to the conclusion that the plaque-inhibitory activities of interferon and each arabinoside tested are statistically independent.-It should be noted that in these experiments cell cultures were first treated with interferon to establish an antiviral state; the interferon was removed at the time of infection, and infected cultures were then maintained in interferon-free medium containing arabinosides. Therefore, the results also allow us to conclude that treatment with arabinosides postinfection does not destabilize the antiviral state previously induced by interferon, and also that interferon pretreatment does not interfere with the subsequent action of these arabinosides in infected cells.
Our results show that at doses of arabinosides giving intermediate plaque inhibition, there is no synergy at any dose of interferon tested. These results do not preclude possible synergy or antagonism between interferon and higher doses of arabinosides. However, the doses of arabinosides used in our experiments are comparable with serum levels of Ara-A and Ara-Hx achieved after intravenous administration of Ara-A in clinical trials (Y. Bryson and J. D. Connor, in preparation).
In addition, measurement of plaque inhibition is equivalent to measurement of inhibition of viral infectivity, but does not address the yield of progeny virus per infected cell. Hence, our data do not rule out the possibility of synergy between the effects of arabinosides and interferon on virus yields.
Lerner and Bailey (19) reported that the plaque-inhibitory effects of human leukocyte interferon and Ara-A were synergistic in a system using Vero cells infected with HSV-1. Our results do not corroborate this report, and we presume that the discrepancy may arise from the following facts. (i) Lerner and Bailey used a definition of synergy that is not meaningful in the absence of more complete dose-response information and depends, in particular, on the slope of the dose-response curves. When their data (19, In summary, our results indicate that for vaccinia virus and HSV-2 in HSF, the plaqueinhibitory activities of arabinosides and interferon are statistically independent, with no evidence for synergy or antagonism. Arabinosides do not destabilize the antiviral state induced by previous exposure to interferon, and previous exposure to interferon does not antagonize the subsequent activity of the arabinosides. In addition, neither ADAI nor the arabinosides affect the induction of interferon synthesis by either virus (NDV) or poly(I:C), and are not themselves interferon inducers.
